| 梁东启,张 庚,冯桂银,王海伦,樊 艳,袁 媛,路桂军.肝癌疼痛与血浆VEGF、BDNF、FGF-2水平的相关性研究[J].现代生物医学进展英文版,2020,(15):2979-2982. |
| 肝癌疼痛与血浆VEGF、BDNF、FGF-2水平的相关性研究 |
| A Correlative Study on the Plasma VEGF, BDNF and Fgf-2 Levels with Liver Cancer Pain |
| Received:February 24, 2020 Revised:March 20, 2020 |
| DOI：10.13241/j.cnki.pmb.2020.15.037 |
| 中文关键词: 肝癌疼痛 血管内皮生长因子 脑源性神经营养因子 纤维细胞生长因子-2 |
| 英文关键词: Liver cancer pain Vascular endothelial growth factor Brain-derived neurotrophic factor Fibroblast growth factor-2 |
| 基金项目:河北省沧州市科学技术局项目(162302119) |
| Author Name | Affiliation | E-mail | | LIANG Dong-qi | Department of pain, Cangzhou Central Hospital, Cangzhou, Hebei, 061001, China | lqd20191105@163.com | | ZHANG Geng | Department of pain, Cangzhou Central Hospital, Cangzhou, Hebei, 061001, China | | | FENG Gui-yin | Department of pain, Cangzhou Central Hospital, Cangzhou, Hebei, 061001, China | | | WANG Hai-lun | Department of pain, Cangzhou Central Hospital, Cangzhou, Hebei, 061001, China | | | FAN Yan | Cangzhou Central Hospital, daytime surgery department, Cangzhou, Hebei, 061000, China | | | YUAN Yuan | Department of pain, Cangzhou Central Hospital, Cangzhou, Hebei, 061001, China | | | LU Gui-jun | Beijing Changgeng Hospital Affiliated to Tsinghua University, pain surgery, Beijing, 102218, China | |
|
| Hits: 640 |
| Download times: 415 |
| 中文摘要: |
| 摘要 目的：研究肝癌疼痛与血浆血管内皮生长因子(VEGF)、脑源性神经营养因子(BDNF)、纤维细胞生长因子-2(FGF-2)水平的相关性。方法：选择我院2018年10月~2019年7月收治的30例肝癌疼痛患者作为研究对象，依据疼痛程度分为4例轻度疼痛组、19例中度疼痛组、7例重度疼痛组，同期纳入30例肝癌无痛患者和30例健康对照组，比较各组血浆VEGF、BDNF和FGF-2水平，并分析肝癌疼痛患者血浆VEGF、BDNF和FGF-2水平和数字评分法(NRS)评分的相关性。结果：肝癌疼痛组血浆VEGF、BDNF、FGF-2水平显著高于肝癌无痛组及对照组(P<0.05)。重度疼痛组血浆VEGF、BDNF、FGF-2水平显著高于中度疼痛组及轻度疼痛组(P<0.05)。治疗后，肝癌疼痛患者血浆VEGF、BDNF、FGF-2水平显著低于治疗前(P<0.05)。肝癌疼痛患者血浆VEGF、BDNF、FGF-2水平和NRS评分呈显著正相关（r值分别为0.619、0.571、0.563，P值均<0.001）。结论：肝癌疼痛患者血浆VEGF、BDNF和FGF-2水平较肝癌无痛者明显上升，且和疼痛程度显著相关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the correlation between liver cancer pain and plasma levels of vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF) and fibroblast growth factor-2 (FGF-2). Methods: Thirty patients with liver cancer pain admitted to our hospital from October 2018 to July 2019 were selected as the research object. According to the degree of pain, they were divided into 4 cases in mild pain group, including 19 cases in moderate pain group and 7 cases in severe pain group. At the same time, 30 painless patients with liver cancer and 30 healthy control groups were included. The levels of plasma VEGF, BDNF and FGF-2 were compared between different groups, and the correlation between the levels of plasma VEGF, BDNF and FGF-2 in patients with liver cancer pain and the score of digital scoring method (NRS) was analyzed. Results: The plasma VEGF, BDNF and FGF-2 levels in liver cancer pain group were significantly higher than those in liver cancer patients without pain and control group (P<0.05). The plasma VEGF, BDNF and FGF-2 levels in the severe pain group were significantly higher than those in the moderate pain group and the mild pain group (P<0.05). After treatment, the plasma levels of VEGF, BDNF and FGF-2 in patients with liver cancer pain were significantly lower than before treatment (P<0.05). The plasma VEGF, BDNF, FGF-2 levels and NRS scores were significantly positively correlated liver cancer pain (r values were 0.619, 0.571 and 0.563, P values<0.001). Conclusion: The plasma VEGF, BDNF and FGF-2 levels in patients with liver cancer pain are significantly higher than those in liver cancer patients without pain, and are significantly related to the degree of pain. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
